Dragonfly Therapeutics, Inc. has licensed two TriNKET immunotherapy drug candidates to Celgene Corp. and its affiliates for $12 million each plus milestones and royalties. The licenses represent the first two of four hematological cancer targets from the companies’ June 2017 collaboration, which was recently expanded to provide Celgene with the option to license products for an additional four-targets, bringing the total to eight. “These licenses provide Celgene exclusive worldwi...